Ryohei Katayama

カタヤマリョウヘイ | Ryohei Katayama

Affiliation and department：
Homepage URL (1)： http://kaken.nii.ac.jp/d/r/60435542.ja.html

Research field (2)： Tumor biology , Pathobiochemistry

Research keywords (9)： cancer immunotherapy , molecular targeted cancer therapy , 多剤耐性 , がん幹細胞 , ABCトランスポーター , acquired resistance , cancer , 薬学 , cellular signal transduction

Research theme for competitive and other funds (17)：

2024 - 2027 Analysis of cell survival signals and tumor microenvironment in the drug-tolerant persister cells
2022 - 2026 Searching druggable target sites by developing refined molecular dynamic simulations
2022 - 2024 Oct4陽性肺癌幹細胞マウスモデルの樹立と癌幹細胞を根絶する革新的治療法の開発
2020 - 2024 臨床がんの遺伝子情報維持に必要な物理化学的因子の解明とがん個別化医療への応用
2020 - 2022 Molecular mechanisms of paradoxical growth suppression by over activation of oncogene kinases

Show all

Papers (114)：

Tianyi Huang, Satoshi Takagi, Sumie Koike, Ryohei Katayama. Inhibition of anti-apoptotic Bcl-2 family members promotes synergistic cell death with ER stress inducers by disrupting autophagy in glioblastoma. Cell Death Discovery. 2025
Takahiro Utsumi, Hayato Mizuta, Yosuke Seto, Ken Uchibori, Makoto Nishio, Isamu Okamoto, Ryohei Katayama. AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts. Cancer Science. 2025
Yosuke Miyashita, Ken Tajima, Kenta Izumi, Naohisa Matsumoto, Daisuke Hayakawa, Ikuko Takeda Nakamura, Isana Katayama, Adityo Wibowo, Hironari Matsuda, Wira Winardi, et al. Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors. Cancer science. 2025
Kohei Maruyama, Yuki Shimizu, Yumi Nomura, Tomoko Oh-Hara, Yuki Takahashi, Satoshi Nagayama, Naoya Fujita, Ryohei Katayama. Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization. NPJ precision oncology. 2025. 9. 1. 4-4
Satoshi Takagi, Mikako Nakajima, Sumie Koike, Miho Takami, Yoshiya Sugiura, Seiji Sakata, Satoko Baba, Ai Takemoto, Tianyi Huang, Yosuke Seto, et al. Frequent copy number gain of MCL1 is a therapeutic target for osteosarcoma. Oncogene. 2024

ｍore...

MISC (35)：

藤村多嘉朗, 横山俊秀, 内堀健, 宮内栄作, 林秀敏, 片山量平. 患者由来ALK融合遺伝子陽性肺がん細胞株を用いたdrug tolerant persisterに対する新規併用療法の探索. 肺癌. 2022. 62. 6. 654-654
片山量平, きょう博, 清谷一馬, 西尾誠人, 竹内賢吾, 藤田直也. 臨床検体と同系マウスゼノグラフトモデルを駆使した抗PD-L1抗体耐性機構の探索. 日本免疫治療学会学術集会プログラム・抄録集. 2020. 17th
Bo Gong, Kazuma Kiyotani, Seiji Sakata, Ken Takahashi, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, et al. Identification of secreted PD-L1 variants as a decoy of PD-L1 blockade antibody mediating the therapeutic resistance. MOLECULAR CANCER THERAPEUTICS. 2019. 18. 12
Koutaroh Okada, Mitsugu Araki, Tomoko Oh-hara, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama. Predication of lorlatinib resistance mechanisms and therapeutic strategies to overcome the resistance in ALK rearranged non-small cell lung cancer. MOLECULAR CANCER THERAPEUTICS. 2019. 18. 12
片山量平, キョウハク, 清谷一馬, 竹内賢吾, 西尾誠人, 藤田直也. 免疫チェックポイント阻害薬抵抗腫瘍の多様性と治療抵抗性機構の解析. 日本がん免疫学会総会プログラム・抄録集. 2019. 23rd

ｍore...

Patents (24)：

ｍore...

Education (3)：

2003 - 2006 The University of Tokyo Graduate School of Pharmaceutical Sciences Department of Pharmaceutical Technology
2001 - 2003 The University of Tokyo Graduate School of Pharmaceutical Sciences Department of Pharmaceutical Technology
1997 - 2001 The University of Tokyo Faculty of Pharmaceutical Sciences

Work history (5)：

2017/10 - 現在 Japanese Foundation for Cancer Research Cancer Chemotherapy Center Chief
2015/10 - 2017/09 Japanese Foundation for Cancer Research Cancer Chemotherapy Center Senior Staff Scientist
2012/07 - 2015/09 Japanese Foundation for Cancer Research Cancer Chemotherapy Center Staff Scientist
2010/04 - 2012/07 Massachusetts General Hospital Cancer Center Postdoc research fellow (JSPS fellowship)
2006/04 - 2010/03 財団法人癌研究会癌化学療法センター基礎研究部研究員

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page